Elastrin Therapeutics Inc.

Restoring the Elastic of Life


"This new delivery system may prove especially useful for patients with cardiovascular disease...Fixing the vessels may ultimately reverse the course of the disease."

Dr. Francis Collins
Director, US National Institute of Health

About Us

Elastrin is a biotechnology startup developing a groundbreaking new treatment capable of reserving tissue and organ calcification.

 Our Mission 

Leveraging our platform technology to develop therapeutics that render calcified tissue and organs supple again

 Our Special Achievement

Proof of principle reversing hardening of arteries and inflammatory tissue damage in arterial and lung disease models. The potential is described at top of this page from an analysis by U.S.. National Institutes of Health Director Dr. Francis Collins.

 
 

Publications

 
 

Our Technology

Elastin degradation is a leading contributor to heart disease, aneurysms and COPD. Learn more

Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.

 

The platform significantly improves the efficacy of drugs and eliminates side-effects by combining particle design with elastin targeting.

Meet the Team

Our interdisciplinary team has extensive track records in antibody development, bioengineering, molecular medicine, medical engineering, and environmental health as well as regulatory approvals, and finance & management. Our team members have a proven track record in entrepreneurship and successful startups.

 

Intellectual Property 

The patent is pending on the targeting therapy.

Further Information

Get in Touch

We’re happy to hear from you. Contact us today to learn more about our business, what we are up to and how you can support us.